Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Metabolism of [14C] BMS-986256 in Healthy Males
NCT04269356Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of afimetoran in systemic lupus erythematosus (SLE), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 49 days, Time to attain maximum observed plasma concentration up to 49 days and 1 more. Started Feb 2020; status: completed.
02
Drugs
afimetoran
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04269356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04269356.